Immunological activation following transcutaneous delivery of HR-gp100 protein

Shoshana Frankenburg, Igor Grinberg, Ziva Bazak, Lena Fingerut, Jacob Pitcovski, Raphael Gorodetsky, Tamar Peretz, Ram M. Spira, Yehuda Skornik, Ronald S. Goldstein

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.

Original languageEnglish
Pages (from-to)4564-4570
Number of pages7
Issue number23
StatePublished - 6 Jun 2007

Bibliographical note

Funding Information:
This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.


  • Langerhans cells
  • Melanoma
  • Transcutaneous vaccination


Dive into the research topics of 'Immunological activation following transcutaneous delivery of HR-gp100 protein'. Together they form a unique fingerprint.

Cite this